The company uses proprietary AI technology to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients globally. Evaxion has a broad pipeline of product candidates, including patient-specific cancer immunotherapies and vaccines to prevent bacterial and viral infections. The company has three proprietary AI platforms: PIONEER, EDEN, and RAVEN, focused on immuno-oncology, bacterial diseases, and viral diseases, respectively. Two of its lead product candidates, EVX-01 and EVX-02, are currently in Phase I/IIa clinical development for the treatment of various cancers.